NCT05718869View on ClinicalTrials.gov

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

October 19, 2025

Study Completion Date

October 19, 2025

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Tafasitamab

Given IV

DRUG

Zanubrutinib

Given PO

Trial Locations (3)

33146

RECRUITING

University of Miami Sylvester Comprehensive Cancer Center, Miami

91010

RECRUITING

City of Hope Medical Center, Duarte

92618

RECRUITING

City of Hope at Irvine Lennar, Irvine

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER